Other NE inhibitors, such as AZD9668 (AstraZeneca) and BAY-678 (Bayer), have undergone clinical trials for the treatment of COPD (Gunawardena et al., 2013; von Nussbaum et al., 2015), and thus may provide potential alternative therapies to prevent alveolar-capillary damage in patients with COVID-19. The gene discussed is ELANE; the disease is chronic obstructive pulmonary disease.